24744-58-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3,5-Dibromo-4-hydroxyphenylacetic acid is employed as a precursor in the synthesis of new drugs due to its promising antioxidant and antimicrobial properties. Its unique chemical structure and functional groups allow for further derivatization and modifications, enhancing its biological and pharmacological properties for the development of innovative treatments.
Used in Antioxidant Applications:
In the field of health and wellness, 3,5-Dibromo-4-hydroxyphenylacetic acid is used as an antioxidant agent to combat oxidative stress and related diseases. Its ability to neutralize free radicals and protect cells from damage makes it a valuable component in the formulation of health supplements and pharmaceuticals aimed at promoting overall health.
Used in Antimicrobial Applications:
3,5-Dibromo-4-hydroxyphenylacetic acid is utilized as an antimicrobial agent in various industries, including pharmaceuticals and cosmetics, to inhibit the growth of harmful microorganisms. Its effectiveness against a range of bacteria and fungi contributes to the development of new antimicrobial products for medical and personal care use.
Used in Chemical Synthesis:
In the chemical industry, 3,5-Dibromo-4-hydroxyphenylacetic acid is used as a building block for the synthesis of various organic compounds and materials. Its versatile structure and reactivity make it suitable for the creation of new chemical entities with diverse applications in different fields.

InChI:InChI=1/C8H6Br2O3/c9-5-1-4(3-7(11)12)2-6(10)8(5)13/h1-2,13H,3H2,(H,11,12)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 

Downstream Products

• 24742-03-8 2,6-dibromo-4-hydroxy-4-hydroxycarbonylmethylcyclohexa-2,5-dien-1-one 
• 1258845-80-5 2-(4-tert-butylbenzyl)-3-[2-(3,5-dibromo-4-hydroxyphenyl)acetamido]propyl pivalate 
• 24744-59-0 3,5-dibromo-4-hydroxyphenylacetic acid ethyl ester 
• 153535-66-1 4-acetoxy-2,6-dibromo-4-carbamoylmethylcyclohexa-2,5-dien-1-one 
• 86255-01-8 4-<(ethoxycarbonyl)methyl>-2,6-dibromo-4-hydroxycyclohexadienone 
• 17194-96-6 2-(3,5-dibromo-4-hydroxyphenyl)acetamide 
• 24744-57-8 2,6-dibromo-4-hydroxy-4-ethoxycarbonylmethylcyclohexa-2,5-dien-1-one 
• 17194-81-9 2,6-dibromo-4-hydroxy-4-carbamoylmethylcyclohexa-2,5-dien-1-one 
• 212688-02-3 3,5-dibromo-4-hydroxyphenylacetic acid methyl ester 

Relevant academic research and scientific papers

Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin

As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3- methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I > Br > Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with Ki (ant) = 2.77 and 2.19 nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6′-iodononivamide.

4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents

Compounds of general formula (I) STR1 wherein R 1 is (CH 2) n ((CHNR 7 R 8) m C(O)R 9 ; n=1-3; and m=0 or 1;R 3 and R 5 are independently Cl, Br, I, or CH 3 ;R 7 and R 8 are independently H or (C 1 -C 4)alkyl;R 9 is OH, (C 1 -C 4)alkoxy, or NR 7 R 8 ;R 31 is H, Cl, Br, I, (C 1 -C 4)alkyl, (C 4 -C 6)cycloalkyl, (C 1 -C 4)haloalkyl, (C 4 -C 6)halocycloalkyl, or --CH(R 10)Ar where Ar is selected from 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, and 6-methoxypyridazin-3-yl N-oxide and R 10 is H or (C 1 -C 4)alkyl;R 41 is OH or a bioprecursor thereof; and the pharmaceutically acceptable salts thereof; are structural analogs of the thyroid hormones T 3 and T 4 and exhibit selective thyromimetic activity. Pharmaceutical compositions of the novel compounds and their use for the treatment of mammalian cholesteremia are provided.